Curis announces data from ongoing TakeAim Leukemia study

Curi announced updated data from the ongoing TakeAim Leukemia study, or CA-4948-102, in relapsed/refractory, or R/R, AML to be presented at the ASCO and EHA conferences. This update includes data for 25 new patients in the FLT3 mutation, or FLT3m, and U2AF1/SF3B1 Splicing Factor mutation, or SFm, cohorts who had received fewer than 3 lines of prior therapy and were treated with emavusertib as monotherapy at the Recommended Phase 2 Dose, or RP2D, of 300 mg BID. 12 R/R AML patients with FLT3m were treated with emavusertib. Prior therapies included venetoclax, hypomethylating agents or HMA, and FLT3 inhibitors. Preliminary data show 6 objective responses in 11 response-evaluable patients: 3 complete remission, or CR, 1 CR with partial hematologic recovery, or CRh, and 2 morphologic leukemia-free state, or MLFS, with on-treatment duration range of 46-324 days. 4 patients are ongoing at the data-cutoff, including 1 CRh and 1 MLFS. 3 of 3 patients who were naive to FLT3i treatment achieved objective response, 3 of 8 patients who progressed on, or following, prior FLT3i treatment achieved objective response, 1 patient is not response-evaluable. All responders demonstrated complete normalization of blast counts in the bone marrow. One of these patients proceeded to allogenic stem cell transplantation. Responses were achieved rapidly in this population, with 5 of 6 responses occurring within one cycle of treatment.